Does changing the composition of buffered eye-drops prevent undesired side effects?
Clinical observations show that topical use of artificial tears containing phosphate on injured eyes may lead to sight-threatening corneal complications. Simulation of such treatment conditions by the EVEIT convincingly demonstrates that changes in the composition of the pharmaceutically used treatments can prevent this undesired side effect. Although considerable healing was achieved during the repeated application of eye-drops, using either a phosphate or citrate buffer, only the drops containing citrate did not develop corneal calcification on the eye. The authors therefore recommend discontinuing the use of phosphate-buffered eye-drops, or other topically applied solutions, to avoid further injury to the patient.
Extrasystoles in TCM failed to elicit PESP in affected LV segments despite viability in those segments, in turn implicating a calcium handling abnormality in TCM. Potential explanations of our results may be that catecholamine excess caused maximum calcium release so that an extrasystole could not enhance contractility any further, or that there is a regional insensitivity to calcium release due to a disturbance of the calcium regulatory system at the molecular level despite the bolus of calcium availability provided by the extrasystole.